Theravance Biopharma R&d Ip, LLC

Theravance, Inc.

Cameron Smith

Paul Ross Fatheree

Lori Jean Van Orden

Steven D E Sullivan

Gary E L Brandt

Melissa Fleury

Adam D Hughes

Roland Gendron

Glenn D Crater

Melanie A Kleinschek

Daniel D Long

YongQi Mu

Craig Husfeld

Corbin Thompson

Lan Jiang

John R Jacobsen

Li Li

Ryan Hudson

Yuhua Ji

Rick Andrew Lee

Anne-Marie Beausoleil

Johnny Uy

Robert Murray McKinnell

Miroslav Rapta

Yu-Hua Ji

Venkat R Thalladi

Pierre-Jean Colson

Paul Allegretti

Marta Dabros

YuHua Ji

Gene Timothy Fass

Tom M Lam

Noah M Benjamin

Gary Brandt

Christina Owens

Gabrielle Elaine Dolgonos

Philip Gerken

Gary EL Brandt

Steven DE Sullivan

The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.

Dimethyl amino azetidine amides as JAK inhibitors

Provided herein are compounds of formula (I): and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janus kinase (JAK) inhibitors. Also provided herein are pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat, e.g., inflammatory and fibrotic diseases, including respiratory diseases.

Imidazolo indazole compounds as JAK inhibitors

The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK inhibitors containing a 4-membered heterocyclic amide

The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

JAK kinase inhibitor compounds for treatment of respiratory disease

5 to 7 membered heterocyclic amides as JAK inhibitors

The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Fused imidazo-piperidine JAK inhibitors

The invention provides compounds of formula (I):  which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.

Growing community of inventors

San Bruno, CA, United States of America

Cameron Smith